Format

Send to

Choose Destination
Med J Aust. 2008 Sep 15;189(6):306-10.

A 5- versus 3-day course of oral corticosteroids for children with asthma exacerbations who are not hospitalised: a randomised controlled trial.

Author information

1
Royal Children's Hospital, Brisbane, QLD, Australia. annechang@ausdoctors.net

Abstract

OBJECTIVE:

To determine whether a 5-day course of oral prednisolone is superior to a 3-day course in reducing the 2-week morbidity of children with asthma exacerbations who are not hospitalised.

DESIGN, SETTING AND PARTICIPANTS:

Double-blind randomised controlled trial of asthma outcomes following a 5-day course of oral prednisolone (1 mg/kg) compared with a 3-day course of prednisolone plus placebo for 2 days. Participants were children aged 2-15 years who presented to the emergency departments of three Queensland hospitals between March 2004 and February 2007 with an acute exacerbation of asthma, but were not hospitalised. Sample size was defined a priori for a study power of 90%.

MAIN OUTCOME MEASURES:

Difference in proportion of children who were symptom-free at Day 7, as measured by intention-to-treat (ITT) and per-protocol analysis; quality of life (QOL) on Days 7 and 14.

RESULTS:

201 children were enrolled, and there was an 82% completion rate. There was no difference between groups in the proportion of children who were symptom-free (observed difference, 0.04 [95% CI, - 0.09 to 0.18] by ITT analysis; 0.04 [95% CI, - 0.17 to 0.09] by per-protocol analysis). There was also no difference between groups in QOL (P = 0.42). The difference between groups for the primary outcome was within the equivalence range calculated post priori.

CONCLUSION:

A 5-day course of oral prednisolone confers no advantage over a 3-day course for children with asthma exacerbations who are not hospitalised.

TRIAL REGISTRATION:

Australian Clinical Trials Registry ACTRN012605000305628.

PMID:
18803532
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Australasian Medical Publishing Company
Loading ...
Support Center